Patent 6,602,911 Scope and Claims for Milnacipran Method-of-Treatment of Fibromyalgia (FMS): What Is Covered, What Is Not, and How the US Patent Landscape Looks
US Patent 6,602,911 is a US method-of-use patent centered on treating fibromyalgia syndrome (FMS) by administering milnacipran (or a pharmaceutically acceptable salt) to a subject, with additional dependent claim limitations tied to human treatment, dose ranges, and sustained-release (SR) formulation. The independent claim is drafted broadly around “method of treating FMS” with milnacipran as the active ingredient, while the most constraining coverage arises in the dependent claims limiting (i) human use, (ii) daily dose windows, and (iii) SR dosage forms.
What does US Patent 6,602,911 claim protect for fibromyalgia?
Short answer: The patent protects a method of treating fibromyalgia syndrome using milnacipran at effective amounts to treat the condition’s chronic pain and fatigue, with narrower protection in dependent claims for humans, specific daily dose ranges, and sustained-release dosing.
Claim 1 (independent): broad method-of-use coverage
Claim 1 requires four core elements:
- A method of treating fibromyalgia syndrome (FMS)
- Administering a composition to an animal subject suffering from FMS
- The composition’s active ingredient consists of milnacipran or a pharmaceutically acceptable salt
- The amount is effective to treat chronic pain and fatigue associated with FMS
Scope implications
- Active-ingredient “consists of” language: claim 1 is limited to compositions where the active ingredient consists of milnacipran (or its salts). This can matter if a competitor tries to add another active ingredient (even if milnacipran is present). If a formulation includes additional actives beyond milnacipran/salts, it is outside the literal wording of claim 1.
- Composition vs. method framing: the claim is a method claim, but it ties method infringement to a composition with milnacipran as the active ingredient.
- FMS treatment includes pain and fatigue: the claimed therapeutic effect is treatment of both chronic pain and fatigue. A design-around that aims only at one symptom domain can be attacked on claim construction, though in practice FMS labels and trials treat the syndrome’s pain and associated symptom burden together.
Claim 2 (dependent): human-specific use
Claim 2 narrows claim 1 by specifying the animal subject is a human. If a competitor were to argue non-human use, claim 2 blocks that path.
Claims 3, 5–7 (dependent): daily dose windows
The dose-dependent claims constrain infringement to administration regimens within defined daily mg ranges:
- Claim 3: 25 mg to 400 mg per day
- Claim 5: at least 100 mg per day
- Claim 6: between 100 and 400 mg per day
- Claim 7: between 100 and 250 mg per day
Scope implications
- The windows overlap heavily. If you map them on a timeline for dosing, nearly all “commercially relevant” milnacipran daily dosing regimens likely sit between 100 and 250 mg/day or 100 to 200 mg/day depending on product and prescriber titration, placing many real-world regimens in claims 5–7 territory.
- Claim 3 is broader (25–400 mg/day), covering lower and upper ends beyond claims 5–7.
Claim 4 (dependent): sustained-release formulation limitation
Claim 4 limits claim 1 to cases where the milnacipran is formulated in a sustained release dosage formulation.
Scope implications
- If a competitor uses immediate-release (IR) milnacipran rather than SR, claim 4 may not be literally met. However, independent claim 1 is not tied to SR in your provided claim set; so SR is only required for claim 4, not for claim 1/2/3/5–7 (based on your listed claims).
- If the product is an ER form (extended release) versus SR, claim construction becomes key: “sustained release” can be interpreted to capture certain extended-release technologies depending on specification and prosecution history, but that interpretive analysis requires the actual patent specification and claim interpretation record.
How does claim language “active ingredient consists of milnacipran” affect infringement risk?
Short answer: The “consists of” active-ingredient phrasing is a high-leverage boundary. It tends to exclude combination-active regimens that include additional actives.
Literal vs. practical design-around options
- Adding another active ingredient alongside milnacipran can reduce literal compliance with claim 1 because the active ingredient would no longer “consist of” milnacipran/salt.
- Changing salt forms typically does not avoid infringement because the claim includes “pharmaceutically acceptable salt thereof.”
- Changing route (oral vs. other) is not listed in your claim excerpt, so it is unlikely to avoid claim 1 unless the composition is not a milnacipran-only composition or the dose and FMS treatment scope fail.
What is the effective range of coverage based on the dependent dose claims?
Short answer: The dependent claims create several overlapping “sweet spots” that likely bracket common clinical dosing practices.
Dose claim map
| Claim |
Daily milnacipran amount limitation |
Practical coverage read-through |
| 3 |
25 to 400 mg/day |
Broad cover across typical titration ranges |
| 5 |
at least 100 mg/day |
Covers mid-to-high dosing regimens |
| 6 |
100 to 400 mg/day |
Strong middle-upper band |
| 7 |
100 to 250 mg/day |
Narrow band within typical label dosing patterns |
Risk concentration
- If a competitor’s regimen is 100–250 mg/day, it potentially hits claims 5–7 and likely claim 3.
- If a regimen is below 100 mg/day (e.g., 25–75 mg/day), it may avoid claims 5–7 but still fall within claim 3 and claim 1.
Does US 6,602,911 protect sustained-release milnacipran for FMS?
Short answer: Yes, claim 4 adds a formulation constraint for sustained-release dosing, but only within that dependent claim. Independent claim 1 remains not tied to SR in the claim text you supplied.
What counts as “sustained release” for claim 4?
- The claim excerpt does not define “sustained release.”
- The patent’s specification would control the term’s meaning in claim construction, which is not included in your prompt. Without that, the safe analytical takeaway is only that claim 4 is tied to SR dosage forms, and the product’s release profile is the gating factor.
What generic entry risks exist for milnacipran-based FMS therapies under this patent?
Short answer: Generic and label-matching products that prescribe milnacipran at effective FMS doses likely face infringement exposure for method-of-use claims unless they carve around the claim limitations (dose window and/or SR depending on which claim theory is asserted).
Likely enforcement theories
- Induced or contributory infringement arguments typically anchor on prescribing and dispensing instructions aligned to the claimed method.
- If a generic is marketed for FMS and the dosing instructions fall within 25–400 mg/day, or within 100–250 mg/day, it maps onto multiple dependent claims (3, 5–7), increasing litigation leverage for the patentee.
Design-around routes
- Avoid SR: potentially limits claim 4 exposure, but does not necessarily defeat claim 1/2/3/5–7.
- Dosing outside claimed ranges: lowering below 25 mg/day could avoid claim 3, but clinical practicality and efficacy are usually not credible for FMS treatment.
- Combination product avoidance: adding another active could avoid the “active ingredient consists of milnacipran” language, but only if the competitor genuinely uses additional actives and they are part of the marketed regimen.
How would US 6,602,911 be positioned in the Orange Book landscape for milnacipran?
Short answer: This depends on whether milnacipran products for FMS list US 6,602,911 as a listed patent covering an applicable drug product. The prompt does not provide Orange Book listings, FDA NDA/BLA identifiers, or listing status, so the landscape mapping cannot be generated from the provided information.
What other patents typically surround a milnacipran-fibromyalgia method-of-use estate in the US?
Short answer: In practice, milnacipran-FMS patent families often include at least four clusters: (1) method-of-use for treating FMS, (2) dosing regimens, (3) formulation (IR/ER/SR) patents, and (4) process/manufacturing patents. Your provided content only supplies claim text for US 6,602,911 and not the rest of the estate.
What you can infer from this patent’s claim structure
- Since claim 4 explicitly claims sustained release, the family likely includes at least one formulation-related patent or includes formulation-specific disclosures in the same family.
- Since multiple dose ranges are claimed, prosecution or continuation activity often captures dosing variations and titration strategies.
How strong is the patent estate for milnacipran FMS methods based on claim breadth?
Short answer: Strength is driven by (i) claim 1 breadth around “method of treating FMS” with milnacipran as the sole active ingredient, and (ii) multiple overlapping dose-dependent claims. The main literal carve-out route is adding other active ingredients and, for claim 4 specifically, avoiding sustained-release formulations.
Strength indicators in the provided claims
- Broad independent claim: method-of-use with milnacipran as the sole active ingredient at an effective amount.
- Multiple dependent dose claims: reduces the chance that a different daily mg regimen escapes all dependent limits.
- Human treatment explicitly covered: claim 2 preempts arguments that only non-human treatment was disclosed or intended.
Weakness indicators in the provided claims
- SR dependence only in claim 4: if enforcement focuses on claim 4 alone, SR becomes the key factual lever.
- “Consists of” active limitation: can be a litigation focal point for combination therapy and product composition questions.
How does US 6,602,911 compare with typical fibromyalgia method-of-use claim patterns?
Short answer: This patent resembles the classic “single active ingredient + syndrome treatment + dose range + formulation” pattern that is common for established small molecules facing generic pressure.
Key comparison points
- Many method-of-use patents for psychiatric/neurologic indications claim broader symptom language, but this one specifically targets chronic pain and fatigue, aligning to FMS clinical endpoints.
- Many dosing patents claim one or two regimens; this one claims several overlapping ranges (25–400 mg; at least 100; 100–400; 100–250), which increases infringement overlap across titrated regimens.
Key Takeaways
- US 6,602,911 claim 1 is the core: it covers a method of treating fibromyalgia syndrome using a milnacipran-only composition (milnacipran or pharmaceutically acceptable salt) at an amount effective to treat chronic pain and fatigue.
- Dependent claims narrow the factual box by adding: human subjects (claim 2), daily dose windows (claims 3, 5–7), and sustained-release formulation (claim 4).
- The “consists of milnacipran” active-ingredient language is the most practical literal boundary against combination products.
- Dose claim stacking is significant: regimens in the 100–250 mg/day band likely map to multiple dependent claims, tightening generic entry risk.
- SR only matters for claim 4: avoiding sustained-release may reduce exposure tied to claim 4 but not necessarily to claim 1/2/3/5–7.
FAQs
1) Does US 6,602,911 cover milnacipran for fibromyalgia when used at doses below 100 mg/day?
Claim 3 covers 25 to 400 mg/day, so dosing below 100 mg/day can still fall within claim 3 and the independent claim 1 if all other elements are met.
2) Can a competitor avoid infringement by switching from sustained-release to immediate-release milnacipran?
That targets claim 4 only. It does not, based on your provided claim set, remove risk under claim 1.
3) What is the most direct design-around to the independent claim’s “active ingredient consists of milnacipran” limitation?
Use a regimen where the active ingredient is not limited to milnacipran (for example, a true combination active product), so the composition does not meet the “consists of” limitation.
4) Which dependent claims are implicated if a regimen uses 150 mg/day of milnacipran?
150 mg/day fits within 100–250 mg/day (claim 7), 100–400 mg/day (claim 6), at least 100 mg/day (claim 5), and 25–400 mg/day (claim 3), assuming FMS and effective treatment elements are satisfied.
5) Is US 6,602,911 limited to oral administration?
Your provided claim excerpt does not specify route, so route-based avoidance is not supported by the claim language you supplied.
References
- US Patent 6,602,911.
